Nexstim Plc · OMXHEX:NXTMH
Nexstim — Pareto Securities Health Care Seminar 2015
18 slides from Nexstim's conference presentation, Aug 28, 2015
Slide 1: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Janne Huhtala | CEO | Nexstim Pareto Securities Health Care Seminar 28.8.2015 @NexstimOyj
Slide 2: Important information
Important information This document and the information contained herein are being presented by Nexstim Oyj FORWARD-LOOKING STATEMENTS (“Nexstim” or the “Company”). In connection with any presentation or review of this This document may contain forward-looking statements that reflect the Company’s c
Slide 3: Introduction to Nexstim
Introduction to Nexstim Novel medtech company with strong position in brain navigation technology and software Ongoing CE mark & pivotal Phase Significant FDA III study in unmet need clearance for stroke in post acute e-field based rehabilitation stroke navigation rehabilitation Targeted growth in U
Slide 4: Company Highlights, January – June 2015
Company Highlights, January – June 2015 ● Phase III multi-centre trial in the US for stroke therapy progressing according to plans ● Successfully enrolling patients on time with first milestone interim analysis expected in Q3 2015 ● 55.4 % revenue growth vs H1 2014 ● Board appointments ● Olli Riikka
Slide 5: Stroke Therapy
Stroke Therapy Huge unmet need and commercial opportunity 5
Slide 6: Positioned within Stroke Care Path
Positioned within Stroke Care Path Days 0-10 Days 10-90 3-12 months from stroke 12 months onwards Acute Stabilisation and Post-acute rehab, Broken care path care spontaneous recovery chronic patients NBT® Acute care to Early rehab and normal healing Currently, patients are discharged from Annual reh
Slide 7: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Nexstim’s Nexstim’sNavigated NavigatedBrain BrainTherapy® Therapy®solution (NBT) Targeting Targetingaablockbuster blockbustermarket… market for stroke solution rehabilitation for stroke rehabilitation (market for post-acute stroke treatment) 2.1 mi
Slide 8: NBT® for stroke rehabilitation – How it works
NBT® for stroke rehabilitation – How it works Validated e-Field Navigation gives Competitive Edge Using a patient’s own MRI scan as a guide, Nexstim Because the injured side is no longer dominated by provides precisely targeted, personalized, the healthy side of the brain, it is more responsive magn
Slide 9: Efficacy demonstrated in Phase II trial
Efficacy demonstrated in Phase II trial Change in upper extremity Fugl-Meyer score from baseline Trial outcome: Absolute average improvement of 20 13.8 Fugl-Meyer scores 15 P<0.05 = difference of "holding an object" and "buttoning a shirt" 84% responder rate (above "MCID" for NBT® group) Difference:
Slide 10: Nexstim's unique technology provides distinct benefits
Nexstim’s unique technology provides distinct benefits Integration of TMS and navigation Several distinct benefits Enhanced limb move ● TMS-navigation integration ● Improved accuracy ● Substantially improved hand ● Navigation is the key differentiator ● Dosing precision movement after treatment ● Re
Slide 11: Highlights in Stroke Rehabilitation (NBT®)
Highlights in Stroke Rehabilitation (NBT®) – 2.1m strokes each year in the US and Europe Huge unmet need – Stroke is the leading cause of long-term disability in Western world – While current standard treatment of physical/occupational therapy is not very Few effective alternatives effective, $8.5bn
Slide 12: Current Status and Outlook
Current Status and Outlook Progressing as planned with milestones 12
Slide 13: Phase III trials - Laying the groundwork for commercialisation
Phase III trials - Laying the groundwork for commercialisation Study in brief Study goals Conducted at 12 top US rehab sites ● Establish clinical efficacy ● Document Rehabilitation Institute of Chicago (central site) of NBT® in upper-limb effects/efficacy of TIRR Memorial Hermann Hospital (Houston)
Slide 14: Status of Clinical Development
Status of Clinical Development Progressing as Planned ● The clinical Phase III multi-center trial is progressing and enrolling patients according to plans. The next interim analysis milestones are estimated to be reached Q3 2015 and Q1 2016 and the clinical evidence is assumed to be ready by the end
Slide 15: IP position
IP position 66 granted patents 72 pending patents Right to software: Nexstim owns rights to its NBT® and NBS Systems’ software developed in- house. Creating hurdles for competitors: e.g. by seeking patent protection on different parts of the products and making it more difficult for potential compet
Slide 16: Key Performance Indicators
Key Performance Indicators EUR in thousands H1 2015 H1 2014 FY 2014 6 months 6 months 12 months Net sales 643.2 413.9 2,210.4 Personnel expenses -1,906.1 -1,641.9 -3,660.2 Depreciation and amortisation -168.7 -125.3 -377.4 Includes 1,745.4 Other operating expenses -3,422.9 -1,672.3 -5,498.5 of Phase
Slide 17: Summary and Future Outlook
Summary and Future Outlook Targeting a Paradigm Shift in Stroke Rehabilitation ● World-leading medical technology and software with game changing potential in stroke rehabilitation ● Good progress since IPO ● NBT® Phase III study proceeding well with interim data due in Q3 2015 and Q1 2016 ● Based o
Slide 18: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Thank you @NexstimOyj